| | | | |
CUSIP No. 75082Q105 | | SCHEDULE 13D | | |
This Amendment No. 1 amends the statement on Schedule 13D filed with the Securities and Exchange Commission by Boxer Capital, LLC, (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), MVA Investors, LLC (“MVA Investors”), Aaron I. Davis and Joe Lewis (collectively with Boxer Capital, Boxer Management, MVA Investors and Aaron I. Davis, the “Reporting Persons”) on May 3, 2021 (the “Schedule 13D”) with respect to the common stock, $0.001 par value per share, of Rain Therapeutics Inc. (the “Issuer”). Capitalized terms used but not defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby amended and supplemented as follows:
The aggregate purchase price of the Common Stock and Non-Voting Common Stock purchased by the Reporting Persons in the Offering is $7,999,995.96. The source of the funding for the purchase of the Common Stock and Non-Voting Common Stock was the general working capital of Boxer Capital. The information set forth in Item 4 below is incorporated herein by reference.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
On November 4, 2022, Boxer Capital agreed to purchase 972,212 shares of Common Stock and 400,000 shares of non-voting common stock at $5.83 per share for an aggregate purchase price of $7,999,995.96 in the Issuer’s registered offering of 5,961,080 shares of Common Stock and 2,615,250 shares of non-voting common stock (the “Offering”), which closed on November 8, 2022. Boxer Capital purchased these shares of Common Stock and non-voting common stock for investment purposes.
Item 5. Interest in Securities of the Issuer.
All percentages are based on 25,126,403 shares of the Issuer’s Common Stock outstanding, which is the sum of (i) 24,763,488 shares of Common Stock outstanding following the completion of the Issuer’s offering, assuming no exercise of the underwriters’ 30-day option to purchase up to an additional 1,286,449 shares of Common Stock, as set forth in the Issuer’s prospectus supplement filed with the SEC on November 7, 2022 and (ii) 362,915 shares of Common Stock that Boxer Capital has the right to acquire upon the conversion of shares of the Issuer’s non-voting common stock on a one-for-one basis.
(a) The Reporting Persons beneficially own in the aggregate 2,510,127 shares of Common Stock which represents 9.99% of the outstanding Common Stock.
Boxer Capital, Boxer Management and Joe Lewis beneficially own 2,510,127 shares of Common Stock which represents 9.99% of the outstanding Common Stock. Boxer Capital owns 3,059,574 shares of non-voting common stock that that because of the Beneficial Ownership Limitation it does not currently have the right to convert into shares of Common Stock. MVA Investors owns 79,726 shares of non-voting common stock that because of the Beneficial Ownership Limitation it does not currently have the right to convert into shares of Common Stock.
The table below reflects options to purchase shares of Common Stock owned by Aaron I. Davis that are not currently exercisable within the next 60 days:
| | | | |
Grant Date | | Number of Non-Vested Options | | Vesting Schedule |
June 1, 2022 | | 20,000 | | Fully vest one year after grant date |
(b) With respect to any rights or powers to vote, or to direct the vote of, or to dispose of, or to direct the disposition of, the Common Stock owned by the Reporting Persons:
(i) Sole power to vote or to direct the vote: